In a report issued on August 2, Jessica Fye from J.P. Morgan maintained a Hold rating on Emergent Biosolutions (EBS – Research Report), with a price target of $37.00. The company's shares closed last Wednesday at $30.72, close to its 52-week low of $26.85. According to TipRanks.com, Fye is a 4-star analyst with an average return of 7.3% and a 48.2% success rate. Fye covers the Healthcare sector, focusing on stocks such as Cerevel Therapeutics Holdings, Crinetics Pharmaceuticals, and Intra-Cellular Therapies. Currently, the analyst consensus on Emergent Biosolutions is a Moderate Buy with an average price target of $51.50.
https://www.tipranks.com/news/blurbs/j-p-morgan-reaffirms-their-hold-rating-on-emergent-biosolutions-ebs?utm_source=advfn.com&utm_medium=referral
Emergent Biosolutions (NYSE:EBS)
Historical Stock Chart
From Nov 2022 to Dec 2022 Click Here for more Emergent Biosolutions Charts.
Emergent Biosolutions (NYSE:EBS)
Historical Stock Chart
From Dec 2021 to Dec 2022 Click Here for more Emergent Biosolutions Charts.